InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $1.815 0.025 (1.40%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$356 March 2026 Quarterly Activity Report and Appendix 4C 30 Apr 2026 8:50AM $2.640 $1.815 fallen by 31.25%
$356 Racura and Wollongong Uni Granted NSW TechVoucher 29 Apr 2026 9:10AM $2.590 $1.815 fallen by 29.92%
$356 Notification of cessation of securities - RAC 24 Apr 2026 10:40AM $2.900 $1.815 fallen by 37.41%
$356 Application for quotation of securities - RAC 23 Apr 2026 12:42PM $3.020 $1.815 fallen by 39.90%
$356 Racura presents MYC silencing data at AACR 2026 22 Apr 2026 11:13AM $3.160 $1.815 fallen by 42.56%
$356 Application for quotation of securities - RAC 16 Apr 2026 12:21PM $3.020 $1.815 fallen by 39.90%
$356 Racura Singapore and HK Investor Briefing Update 9 Apr 2026 2:54PM $2.730 $1.815 fallen by 33.52%
$356 Application for quotation of securities - RAC 9 Apr 2026 1:33PM $2.810 $1.815 fallen by 35.41%
$356 Appendix 3Y - Dr Daniel Tillett 2 Apr 2026 1:43PM $2.650 $1.815 fallen by 31.51%
$356 Application for quotation of securities - RAC 2 Apr 2026 1:40PM $2.630 $1.815 fallen by 30.99%
$356 First Patient Recruited to HARNESS-1 Lung Cancer Trial 31 Mar 2026 1:53PM $2.360 $1.815 fallen by 23.09%
$356 Racura Oncology Symposium Recording Release 30 Mar 2026 5:16PM $2.430 $1.815 fallen by 25.31%
$356 Application for quotation of securities - RAC 26 Mar 2026 2:18PM $2.750 $1.815 fallen by 34%
$356 Racura and Purdue University Partnership Announced 26 Mar 2026 10:16AM $2.810 $1.815 fallen by 35.41%
$356 Racura Oncology Investor Symposium Presentation 24 Mar 2026 1:58PM $2.490 $1.815 fallen by 27.11%
$356 Application for quotation of securities - RAC 19 Mar 2026 2:04PM $2.950 $1.815 fallen by 38.47%
$356 First Patient Dosed Safely with RC220 in Hong Kong 19 Mar 2026 8:55AM $2.380 $1.815 fallen by 23.74%
$356 Racura Selected to Present at 2026 AACR Annual Meeting 18 Mar 2026 8:58AM $2.160 $1.815 fallen by 15.97%
$356 Racura HARNESS-1 Trial Receives Governance Approval 16 Mar 2026 8:56AM $2.170 $1.815 fallen by 16.36%
$356 Application for quotation of securities - RAC 12 Mar 2026 3:05PM $2.270 $1.815 fallen by 20.04%
$356 Application for quotation of securities - RAC 5 Mar 2026 2:48PM $2.370 $1.815 fallen by 23.42%
$356 Racura Oncology Research Symposium Sydney 4 Mar 2026 9:08AM $2.240 $1.815 fallen by 18.97%
$356 Racura Investor Briefing Hong Kong and Singapore 3 Mar 2026 9:15AM $2.410 $1.815 fallen by 24.69%
$356 Appendix 4D & Half-Year Financial Statements 27 Feb 2026 12:31PM $2.520 $1.815 fallen by 27.98%
$356 Application for quotation of securities - RAC 26 Feb 2026 10:57AM $2.400 $1.815 fallen by 24.38%

51 - 75 of 999 results

Page 3 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.